Securities Code: 300119
Securities Abbreviation: Gansu Biologics
Announcement No.: 2026-034
Gansu Biologics Co., Ltd.
Announcement on Subsidiary Obtaining Approval for Production of South African Type 1 Multivalent Foot-and-Mouth Disease Vaccine
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Gansu Biologics Co., Ltd. (hereinafter referred to as the "Company")'s holding subsidiary, Neimenggu Aowei AnTai Biotechnology Co., Ltd. (hereinafter referred to as "Aowei AnTai"), recently received the "Veterinary Drug Product Approval Number Certificate" issued by the Ministry of Agriculture and Rural Affairs. Aowei AnTai's "Bovine and Ovine Foot-and-Mouth Disease O, A, and South African Type 1 Trivalent Inactivated Vaccine" and "Porcine Foot-and-Mouth Disease O and South African Type 1 Bivalent Inactivated Vaccine" have been approved for production. The specific situation is as follows:
I. Product Basic Information